Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on February 4, 2019. The filing primarily references the company's financial results for the fourth quarter and full year ended December 31, 2018, which were detailed in a press release issued on February 7, 2019.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is furnished but not included in the text of this 8-K summary.
Material Changes and Personnel Updates
- Executive Departure: Mai Chan (Grace) Yow, Executive Vice President of Worldwide Manufacturing for Fluidigm Singapore Pte. Ltd. (a wholly-owned subsidiary), notified the company of her intention to retire.
- Timeline: Ms. Yow plans to retire in September 2019 following a transition period.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information regarding financial results is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it is not incorporated by reference into future filings unless specifically cited.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release dated February 7, 2019).
- Confirm the transition plan for the Worldwide Manufacturing role at Fluidigm Singapore following Ms. Yow's retirement.
- Note that the registrant name in the filing is Fluidigm Corporation, distinct from the metadata label "Standard BioTools Inc."